Analysts’ Weekly Ratings Changes for Niagen Bioscience (NAGE)

A number of research firms have changed their ratings and price targets for Niagen Bioscience (NASDAQ: NAGE):

• 11/9/2026 – Niagen Bioscience was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 11/6/2026 – Niagen Bioscience had its price target lowered by Freedom Broker from $8.50 to $6.00. They now have a “buy” rating on the stock.
• 11/6/2026 – Niagen Bioscience had its price target lowered by Canaccord Genuity Group from $9.00 to $7.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Niagen Bioscience had its price target lowered by Canaccord Genuity Group from $10.00 to $9.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Niagen Bioscience had its “hold (c)” rating reaffirmed by Weiss Ratings.

Niagen Bioscience Stock Down 5.7%

NASDAQ NAGE opened at $2.15 on Wednesday. Niagen Bioscience, Inc. has a 52 week low of $2.04 and a 52 week high of $7.28. The stock has a market capitalization of $170.27 million, a PE ratio of 17.92 and a beta of 2.12. The firm has a 50 day moving average of $2.72 and a two-hundred day moving average of $3.79.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). Niagen Bioscience had a net margin of 8.37% and a return on equity of 10.18%. The business had revenue of $27.19 million for the quarter. On average, equities research analysts expect that Niagen Bioscience, Inc. will post 0.04 earnings per share for the current fiscal year.

Niagen Bioscience, Inc. develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes. Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.